Although diagnostic guidelines recommend examining CLL patients for del(17p) but not for TP53 mutations [438], analysis of TP53 mutations alone can help to identify an extra 3% to 6% of CLL patients with poor outcomes who should also be considered for other treatment strategies [432]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.